A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC.

Br J Cancer · 2005 · PMC2361626 · PMID 16222311

Europe PMC DOI

hedged sentence

0.2000

closest p · 4.0× alpha

0.2000

boldest claim

The sentences

a nonsignificant trendP =0.20not close (p > 0.1)

Relative to baseline, at 3 weeks post-CRT, there was a nonsignificant trend towards improvement in scores for loss of appetite ( P =0.20), dyspnea ( P =0.13), haemoptysis ( P =0.14), pain ( P =0.36), overall symptomatic distress ( P =0.19) and overall QOL ( P =0.54) after CRT ( Table 6 ).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.